Opinion

Video

Durvalumab in Endometrial Cancer: DUO-E Trial Updates

Author(s):

Angeles Alvarez Secord, MD, MHSc ,Dana M. Chase, MD, FACOG

Panelists discuss recent updates from the DUO-E trial, highlighting key efficacy and safety data that led to the FDA’s approval of durvalumab for endometrial cancer while examining how this new indication influences treatment strategies for advanced or recurrent cases.

Video content above is prompted by the following:

  • Briefly comment on recent data updates presented for the DUO-E trial and offer insights into the recently approved FDA indication for durvalumab in endometrial cancer. 
  • Briefly comment on key takeaways from efficacy and safety data leading to the new approval.
  • How does the approved indication for durvalumab affect your treatment approach for advanced or recurrent endometrial cancer?
Related Videos
2 KOLs are featured in this series.
5 KOLs are featured in this series.
5 KOLs are featured in this series.
5 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Related Content
Advanced Systemic Mastocytosis: Expert Insight into Epidemiology, Diagnosis, and Treatment
September 15th 2021

Advanced Systemic Mastocytosis: Expert Insight into Epidemiology, Diagnosis, and Treatment